Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
637
datasets available to search
ShareScore release 0.9.0
Dataset results
637 results for “thyroid cancer”
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
ClinicalTrials.gov study NCT00095836. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
ClinicalTrials.gov study NCT00098345. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
ClinicalTrials.gov study NCT03914300. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
ClinicalTrials.gov study NCT00358956. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
ClinicalTrials.gov study NCT02973997. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
ClinicalTrials.gov study NCT01896479. IPD Sharing: Not stated. Countries: 14. Publications: 1.
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
ClinicalTrials.gov study NCT04321954. IPD Sharing: YES. Countries: 1. Publications: 1.
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
ClinicalTrials.gov study NCT01236547. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
ClinicalTrials.gov study NCT02143726. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
ClinicalTrials.gov study NCT00559949. IPD Sharing: Not stated. Countries: 2. Publications: 1.
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
ClinicalTrials.gov study NCT00410761. IPD Sharing: Not stated. Countries: 24. Publications: 1.
Ponatinib for Advanced Medullary Thyroid Cancer
ClinicalTrials.gov study NCT01838642. IPD Sharing: NO. Countries: 1. Publications: 3.
Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
ClinicalTrials.gov study NCT01882816. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
ClinicalTrials.gov study NCT02244463. IPD Sharing: NO. Countries: 1. Publications: 1.
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
ClinicalTrials.gov study NCT01843062. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
ClinicalTrials.gov study NCT00668811. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
ClinicalTrials.gov study NCT04280081. IPD Sharing: YES. Countries: 1. Publications: 5.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
ClinicalTrials.gov study NCT01321554. IPD Sharing: Not stated. Countries: 23. Publications: 7.
Supplementary tables from: Long-term outcomes of patients diagnosed with differentiated thyroid cancer in childhood and young adulthood
Open the record for dataset details and reuse information.
Circulating myeloid-derived suppressor cells facilitate invasion of thyroid cancer cells by repressing miR-486-3p
<p>Background: Myeloid-derived suppressor cells (MDSCs) have become increasingly recognized as facilitators of tumor development. However, the role of MDSCs in papillary thyroid carcinoma (PTC) progression has not been clearly explored.</p> <p>Objective: We aimed to evaluate the levels and function of circulating MDSCs in PTC.</p> <p>Methods: The proportion of circulating polymorphonuclear (PMN)-MDSCs and mononuclearMDSCs from patients with PTC or benign thyroid nodules and healthy controls was measured using flow cytometry. For immunosuppressive activity analysis, sorted circulating MDSCs were cocultured with CD3/CD28-costimulated T lymphocytes and the proliferation of T cells was determined. PTC cell lines (TPC-1 and BC-PAP) were cocultured with PMN-MDSCs, and the effects on cell migration, invasion, proliferation, and apoptosis were evaluated. The differential expressed microribonucleic acids (RNAs) and messenger RNAs and their function were also explored in TPC-1 cells cocultured with or without PMN-MDSCs.</p> <p>Results: PMN-MDSCs were increased in peripheral blood mononuclear cells of patients with PTC. Circulating PMN-MDSCs displayed strong T cell suppressive activity. PTC cells demonstrated enhanced invasive capabilities in vitro and in vivo when cocultured with sorted PMN-MDSCs. PMN-MDSCs decreased expression of miR-486-3p and activated nuclear factor kappa B2 (NF-κB2), a direct target of miR-486-3p. Rescue of miR-486-3p diminished the cell migration and invasion induced by PMN-MDSCs.</p> <p>Conclusion: Collectively, our work indicates that circulating PMN-MDSCs promote PTC progression. By suppressing miR-486-3p, PMN-MDSCs promote the activity of the NF-κB2 signaling pathway, resulting in accelerated invasion of PTC cells, which may provide new therapeutic strategies for treatment of thyroid cancer. </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.